Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. Juni 2014 08:08 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics Completes Global Licensing Agreement With Ligand Pharmaceuticals for the Development of Inhibitors of IRAK4

NEW YORK, June 24, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), announced today an agreement with Ligand Pharmaceuticals Incorporated (Nasdaq:LGND) to license exclusive global rights...
23. Juni 2014 08:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at the 2014 JMP Securities Healthcare Conference

NEW YORK, June 23, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief...
16. Juni 2014 16:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Present at the 2014 Wells Fargo Healthcare Conference

NEW YORK, June 16, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company today announced that Michael Weiss, the Company's Interim Chief...
13. Juni 2014 05:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics' TG-1101 (Ublituximab) in Combination With Ibrutinib Demonstrates Compelling Clinical Activity and Safety Profile in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

90% overall response rate (ORR) at first efficacy assessment for combination of TG-1101 and Ibrutinib No patients have progressed on the combination to date Combination appears well...
30. Mai 2014 13:55 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Presentation of Single Agent Data for Both TG-1101 and TGR-1202 in Ongoing Phase I Clinical Studies

Highlights from TG-1101 Data Include: 100% of CLL patients achieved a peripheral response with 67% achieving a partial response 44% of Indolent NHL patients achieved a complete response...
22. Mai 2014 16:36 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Clinical Data Presentations for TG-1101 and TGR-1202 at the European Hematology Association (EHA) Meeting in Milan, Italy

NEW YORK, May 22, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), today announced upcoming presentations of clinical data for TG-1101, the Company's next generation, glycoengineered...
12. Mai 2014 16:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces First Quarter 2014 Financial Results and Business Update

NEW YORK, May 12, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of...
09. Mai 2014 08:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. to Host Conference Call on First Quarter 2014 Financial Results and Business Update

NEW YORK, May 9, 2014 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), an innovative, clinical-stage biopharmaceutical company, today announced that a conference call will be held on Tuesday,...
08. Mai 2014 08:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Provides Update on a Modified TGR-1202 Formulation and Fed-State Dosing With Data Demonstrating Significantly Higher TGR-1202 Exposure

- Based on healthy subject bioequivalence studies, improvements in absorption are projected to increase exposure levels by approximately 3-4 fold NEW YORK, May 8, 2014 (GLOBE NEWSWIRE) -- TG...
06. Mai 2014 08:30 ET | Quelle: TG Therapeutics, Inc.

TG Therapeutics, Inc. Announces Clinical Data Presentations at Upcoming Conferences

Single Agent Study Updates on TG-1101 and TGR-1202 to be Presented at ASCO 2014 Combination Study Data of TG-1101 plus Ibrutinib to be Presented at EHA 2014 Combination Study Data of...

Vorherige Seite